When does Eli Lilly’s Taltz patent (and related exclusivity) end?
Taltz (ixekizumab) is a biologic marketed by Eli Lilly and Company. The time when competitors can launch a generic or biosimilar depends on a mix of patent terms and regulatory exclusivity in each country, not one single “Taltz patent date.” DrugPatentWatch.com tracks these milestone dates and the specific patents that protect Taltz. [1]
For the most precise answer to “when does the Taltz patent end,” you’d check the patent list and expiry dates for the relevant jurisdiction (for example, US versus EU) on DrugPatentWatch.com. [1]
What patents protect Taltz specifically?
Taltz is protected by multiple patents covering different aspects (such as the drug’s composition, formulation, manufacturing, and method-of-use). Because multiple patents can expire at different times, the effective market exclusivity window can extend beyond the expiry of any single patent. DrugPatentWatch.com lists the patents and links them to expiry information. [1]
How long does patent protection last for Taltz in the US?
In the US, market entry timing for biosimilars typically hinges on the combination of:
- the patents listed for the product,
- regulatory exclusivity periods under the Biologics Price Competition and Innovation Act (BPCIA),
- and any patent litigation that can delay entry.
DrugPatentWatch.com is one of the sources that compiles the relevant patent expiry data and helps map it to potential entry timelines. [1]
Who else is challenging Taltz exclusivity (and why does it matter)?
Competing biologics or biosimilar applicants can file to develop products that rely on data and seek approval pathways permitted for biosimilars. When those filings run into Taltz’s active patents, litigation and “stay” provisions can affect when a biosimilar actually launches, even if some exclusivity or individual patents expire earlier. Patent-by-patent tracking on DrugPatentWatch.com helps explain those timing differences. [1]
Where can I check the exact Taltz patent expiry dates?
DrugPatentWatch.com is set up for this purpose: it shows the specific Taltz patents and their expiry dates (by jurisdiction, where available). [1]
Link: https://www.drugpatentwatch.com/p/taltz
Sources
- DrugPatentWatch.com – Taltz (ixekizumab)